Loomis Sayles & Co. L P Makes New Investment in Cencora, Inc. (NYSE:COR)

Loomis Sayles & Co. L P acquired a new stake in Cencora, Inc. (NYSE:COR) in the 4th quarter, Holdings Channel.com reports. The institutional investor acquired 4,333 shares of the company’s stock, valued at approximately $974,000.

A number of other institutional investors have also modified their holdings of the business. AssuredPartners Investment Advisors LLC acquired a new stake in Cencora during the 4th quarter worth $621,000. NEOS Investment Management LLC boosted its stake in shares of Cencora by 25.6% during the fourth quarter. NEOS Investment Management LLC now owns 6,074 shares of the company’s stock worth $1,365,000 after buying an additional 1,238 shares during the period. Moment Partners LLC purchased a new position in shares of Cencora during the fourth quarter worth about $275,000. Elo Mutual Pension Insurance Co increased its position in Cencora by 15.8% in the 4th quarter. Elo Mutual Pension Insurance Co now owns 18,354 shares of the company’s stock valued at $4,124,000 after acquiring an additional 2,508 shares during the period. Finally, Mitsubishi UFJ Asset Management Co. Ltd. raised its stake in Cencora by 7.6% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 278,286 shares of the company’s stock valued at $63,783,000 after acquiring an additional 19,544 shares during the last quarter. 97.52% of the stock is owned by institutional investors and hedge funds.

Cencora Price Performance

Shares of NYSE COR opened at $275.16 on Friday. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40. The stock has a market cap of $53.36 billion, a price-to-earnings ratio of 39.14, a PEG ratio of 1.31 and a beta of 0.51. The company’s 50-day moving average price is $253.81 and its 200 day moving average price is $241.21. Cencora, Inc. has a 52 week low of $214.77 and a 52 week high of $275.57.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, topping analysts’ consensus estimates of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. As a group, research analysts forecast that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, March 3rd. Investors of record on Friday, February 14th were given a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a yield of 0.80%. The ex-dividend date of this dividend was Friday, February 14th. Cencora’s dividend payout ratio is presently 31.29%.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on COR shares. StockNews.com upgraded Cencora from a “hold” rating to a “buy” rating in a research note on Wednesday, March 12th. Evercore ISI lifted their price objective on shares of Cencora from $270.00 to $280.00 and gave the company an “outperform” rating in a research report on Thursday, February 6th. JPMorgan Chase & Co. upped their price objective on shares of Cencora from $289.00 to $301.00 and gave the stock an “overweight” rating in a research report on Friday, January 24th. Mizuho began coverage on shares of Cencora in a report on Wednesday, December 4th. They issued an “outperform” rating and a $280.00 target price on the stock. Finally, Wells Fargo & Company increased their price target on shares of Cencora from $251.00 to $274.00 and gave the stock an “equal weight” rating in a report on Friday, March 14th. Two research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $280.20.

Insider Activity at Cencora

In other Cencora news, CAO Lazarus Krikorian sold 2,000 shares of the stock in a transaction on Monday, March 10th. The stock was sold at an average price of $260.06, for a total transaction of $520,120.00. Following the transaction, the chief accounting officer now owns 20,154 shares of the company’s stock, valued at $5,241,249.24. This represents a 9.03 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Silvana Battaglia sold 5,000 shares of Cencora stock in a transaction on Friday, February 21st. The shares were sold at an average price of $242.24, for a total value of $1,211,200.00. Following the completion of the sale, the executive vice president now directly owns 15,374 shares of the company’s stock, valued at approximately $3,724,197.76. This represents a 24.54 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 30,675 shares of company stock valued at $8,034,778. 10.80% of the stock is owned by insiders.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.